Tango Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025
Tango Therapeutics (NASDAQ: TNGX) has announced it will release its first quarter 2025 financial results on Monday, May 12, 2025, before U.S. financial markets open. The company has stated that it will not host a conference call to discuss the results.
Tango Therapeutics (NASDAQ: TNGX) ha annunciato che pubblicherà i risultati finanziari del primo trimestre 2025 lunedì 12 maggio 2025, prima dell'apertura dei mercati finanziari statunitensi. La società ha comunicato che non terrà una conference call per discutere i risultati.
Tango Therapeutics (NASDAQ: TNGX) ha anunciado que publicará sus resultados financieros del primer trimestre de 2025 el lunes 12 de mayo de 2025, antes de la apertura de los mercados financieros de EE. UU. La compañía ha indicado que no realizará una conferencia telefónica para discutir los resultados.
Tango Therapeutics (NASDAQ: TNGX)는 2025년 5월 12일 월요일 미국 금융 시장 개장 전에 2025년 1분기 재무 결과를 발표할 예정이라고 밝혔습니다. 회사는 결과에 대해 논의하는 컨퍼런스 콜을 진행하지 않을 것이라고 전했습니다.
Tango Therapeutics (NASDAQ : TNGX) a annoncé qu'elle publiera ses résultats financiers du premier trimestre 2025 le lundi 12 mai 2025, avant l'ouverture des marchés financiers américains. La société a précisé qu'elle n'organisera pas de conférence téléphonique pour discuter des résultats.
Tango Therapeutics (NASDAQ: TNGX) hat angekündigt, seine Finanzergebnisse für das erste Quartal 2025 am Montag, den 12. Mai 2025, vor Öffnung der US-Finanzmärkte zu veröffentlichen. Das Unternehmen teilte mit, dass keine Telefonkonferenz zur Besprechung der Ergebnisse stattfinden wird.
- None.
- None.
BOSTON, May 01, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that it will report first quarter 2025 financial results on May 12, 2025, before the open of the U.S. financial markets. The company does not intend to hold a conference call.
About Tango Therapeutics
Tango Therapeutics is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer. For more information, please visit www.tangotx.com.
Investors and Media:
Elizabeth Hickin
IR@tangotx.com
media@tangotx.com
FAQ
When will Tango Therapeutics (TNGX) report Q1 2025 earnings?
Will Tango Therapeutics (TNGX) hold an earnings call for Q1 2025 results?
What time will TNGX release its Q1 2025 earnings?
